After the extraordinary rally in growth stocks over the summer, the question we frequently hear from investors is whether the market will enter a value rally—perhaps not right now, but over the near to medium term.

We do not have strong views about the potential external triggers of such a value rally, be it government intervention, central bank policy, inflation or political change. However, we believe that earnings—or more precisely, cash flows—are ultimately the drivers of a value rally, in particular the predictability of earnings growth. The more predictable the earnings growth for the market as a whole, the more likely we experience a value rally.

Display 1 illustrates this point. The bars show consensus expectations in terms of 12 months forward EPS growth. The dark blue line shows actual EPS growth. Where the bars and the dark blue line are closely aligned, consensus was broadly right, and where they diverge, earnings have been unpredictable and disappointed expectations. The shaded vertical areas show periods of value rallies, i.e. periods where the MSCI World Value Index outperformed the MSCI World Growth Index. As you can see, value rallies have historically occurred when earnings forecasts were reliable.

This should not be much of a surprise. A value stock is one that is cheap relative to its near-term intrinsic value. The intrinsic value of a company is a function of its future free cash flows, of which earnings are an important component and hence its ability to pay dividends or re-invest in the business. During periods of predictable earnings, value stocks can be attractive.
as they often trade at a discount to intrinsic value due to uncertainty caused by e.g. cyclicality, management or perceived structural issues. In such instances, the gap between price and intrinsic value can be determined fairly easily. When earnings keep disappointing, determining the intrinsic value can become difficult for investors and the discount for uncertainty deepens.

If we look at the value rally from 2003 to July 2007, the stable “Goldilocks” environment made earnings growth predictable and value stocks outperformed. Similarly, during the 2009/10 recovery period, earnings forecasts for cyclical value stocks were reliable and so investors bought into them.

“A value rally is first and foremost an earnings phenomenon, not a valuation phenomenon”

Since 2010 we have gone through nearly 10 years of near-consistent earnings disappointments, driven not only by negative rates, but also technological disruption and political upheaval—first in the Eurozone and then in the U.S./China relationship. Apart from the very brief periods of 2012/13 and 2016 when temporary relief measures created earnings growth that matched up to forecasts, earnings have disappointed and value stocks underperformed.

What matters very little is the relative valuation of value stocks versus growth stocks. The premium in Price Earnings terms between growth stocks and value stocks was fairly stable before and going into the four main value rallies of the last 20 years. In other words, a value rally is first and foremost an earnings phenomenon, not a valuation phenomenon.

The picture emerging in 2020
During the current COVID crisis we have seen by far the largest underperformance of value versus growth of the last 20 years, even though near-term earnings disappointment is no worse than in 2018, for example. This has left us with the biggest relative valuation gap between value and growth since 2000.

“Without earnings growth becoming more predictable, there will be no value rally”

The gap suggests that the market believes that there is more earnings disappointment ahead, i.e. the consensus 35% earnings improvement for the next 12 months will simply not materialise. We do not know whether the market is right, but we are fairly confident that without earnings growth becoming more predictable, there will not be a value rally. And as we have seen in the last 10 years, predictability of earnings is not just a function of economic growth, but also a question of how well companies handle disruption, embrace new technology and—increasingly—how well they deliver on ESG matters. In other words, quite a lot of things need to go right for a value rally to happen.

Quality in a value rally
This brings us to the next question: how does a quality portfolio behave in a value rally? A quality stock as we define it has first and foremost predictable earnings growth at sustainably high returns. In a period when very few companies have predictable earnings, quality stocks tend to outperform. This is mostly on the back of stronger earnings, but also in part due to a higher scarcity premium. In a value rally, this scarcity premium goes
down. However, the predictable earnings growth should not be affected. Therefore, the absolute risk to a quality portfolio lies in valuation, not in earnings. If we look at historical trends and the relative performance of our global strategies, we see that in periods of value rallies (2003-2007, 2009/10, 2012/13 and 2016), generally performance lagged in relative terms but was strong in absolute terms. More recently, we have again seen our global portfolios’ earnings profile showing predictability and resilience even in this unprecedented environment.

“Our global portfolios’ earnings profiles have shown predictability and resilience, even in this unprecedented environment”

Our main concern now is valuation. In the pandemic, companies with predictable earnings profiles have become even scarcer and their valuation premium has gone up. That is particularly true for high growth technology companies and the so-called “COVID-winners”.

Risk Considerations
There is no assurance that a portfolio will achieve its investment objective. Portfolios are subject to market risk, which is the possibility that the market value of securities owned by the portfolio will decline. Market values can change daily due to economic and other events (e.g. natural disasters, health crises, terrorism, conflicts and social unrest) that affect markets, countries, companies or governments. It is difficult to predict the timing, duration, and potential adverse effects (e.g. portfolio liquidity) of events. Accordingly, you can lose money investing in this strategy. Please be aware that this strategy may be subject to certain additional risks. Changes in the worldwide economy, consumer spending, competition, demographics and consumer preferences, government regulation and economic conditions may adversely affect global franchise companies and may negatively impact the strategy to a greater extent than if the strategy’s assets were invested in a wider variety of companies. In general, equity securities’ values also fluctuate in response to activities specific to a company. Investments in foreign markets entail special risks such as currency, political, economic, and market risks. Stocks of small-capitalisation companies carry special risks, such as limited product lines, markets and financial resources, and greater market volatility than securities of larger, more established companies. The risks of investing in emerging market countries are greater than risks associated with investments in foreign developed markets. Non-diversified portfolios often invest in a more limited number of issuers. As such, changes in the financial condition or market value of a single issuer may cause greater volatility.

DEFINITIONS
The indexes are unmanaged and do not include any expenses, fees or sales charges. It is not possible to invest directly in an index. Any index referred to herein is the intellectual property (including registered trademarks) of the applicable licensor. Any product based on an index is in no way sponsored, endorsed, sold or promoted by the applicable licensor and it shall not have any liability with respect thereto. The MSCI World Index is a free float adjusted market capitalization weighted index that is designed to measure the global equity market performance of developed markets. The term “free float” represents the portion of shares outstanding that are deemed to be available for purchase in the public equity markets by investors. The performance of the Index is listed in U.S. dollars and assumes reinvestment of net dividends. The MSCI World Health Care Index is a capitalization weighted index that monitors the performance of health care stocks from developed market countries in North America, Europe and the Asia/Pacific Region. The index includes reinvestment of dividends, net of foreign withholding taxes.

DISTRIBUTION
This communication is only intended for and will only be distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations.

This material is a general communication, which is not impartial and has been prepared solely for informational and educational purposes and does not constitute an offer to subscribe or purchase, whether directly or indirectly, any security or to adopt any specific investment strategy. The information herein has not been based on a consideration of any individual investor circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

Except as otherwise indicated herein, the views and opinions expressed herein are those of the authors. These conclusions are speculative in nature, may not come to pass or be fulfilled in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

Forecasts and estimates provided herein are subject to change and may not actually come to pass. Information regarding expected market returns and market outlooks is based on the research, analysis and opinions of the authors. These conclusions are speculative in nature, may not come to pass and are not intended to predict the future performance of any specific Morgan Stanley Investment Management product.

MSIM has not authorised financial intermediaries to use and to distribute this document, unless such use and distribution is made in accordance with applicable law and regulation.

Additionally, financial intermediaries are required to satisfy themselves that the information in this document is suitable for any person to whom they provide this document in view of that person's circumstances and purpose. MSIM shall not be liable for, and accepts no liability for, the use or misuse of this document by any such financial intermediary.

The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without MSIM's express written consent.

All information contained herein is proprietary and is protected under copyright law.